Uveal melanoma

This phase 3 trial tested a personalized vaccine made from a patient's own immune cells and tumor RNA in 200 people with a high-risk form of eye cancer (uveal melanoma with monosomy 3). After surgery to remove the tumor, half received the vaccine over two years and half were simp…

This trial tests a treatment called Melphalan/HDS for people whose eye melanoma has spread to the liver. The approach delivers high-dose melphalan, a chemotherapy drug, straight into the liver through a device system while limiting exposure to the rest of the body. Researchers wa…

This early-stage trial is testing an experimental drug called AEB1102 in people with advanced solid tumors that have not responded to standard treatments or for which no standard treatment exists. The main goal is to find the highest dose that is safe and to understand the drug's…

This phase 2 trial tested the drug darovasertib in 15 people with high-risk uveal melanoma (a rare eye cancer) who were scheduled for eye removal surgery. Participants took the drug for up to 4 weeks before surgery, and some continued for 6 months afterward. The main goals were t…

This early-phase trial tested a new personalized therapy called TBio-4101 for people with advanced melanoma that had stopped responding to standard treatments. The therapy uses a patient's own tumor-fighting immune cells, which are collected, multiplied in the lab, and then infus…

This study tested a new drug called IMCgp100 in 378 adults with a specific genetic type (HLA-A*0201) of advanced uveal melanoma, a rare eye cancer. Participants received either IMCgp100 or one of three standard treatments (dacarbazine, ipilimumab, or pembrolizumab). The main goal…

This study tested the drug sorafenib (Nexavar) in 32 adults with uveal melanoma that had spread to other parts of the body. The goal was to see if the drug could stop tumors from growing for at least 24 weeks. Sorafenib is already used for other cancers, and researchers wanted to…

This study looked at whether starting supportive care early, alongside standard cancer treatment, helps patients with metastatic uveal melanoma feel more supported. 162 adults with advanced eye cancer that had spread were randomly assigned to get either standard oncology visits o…

This study looked at the DNA changes (mutations) in eye cancers called ocular melanoma. Researchers analyzed tumor samples from 58 patients to understand how these cancers develop and spread. The goal was to identify key mutations that could lead to better treatments in the futur…

This study looked at whether measuring tumor DNA in the blood can help doctors know if surgery to remove liver metastases from uveal melanoma was successful. Researchers took blood samples from 60 patients before and after surgery and during follow-up. The goal was to see if chan…